Valuation: Orexo AB

Market Cap 47.77M 4.84M 4.34M 3.96M 3.62M 6.82M 455M 7.03M 19.05M 243M 18.15M 17.76M 766M P/E 2024
-2.97x
P/E 2025 1.63x
Enterprise Value -373M -37.77M -33.87M -30.96M -28.26M -53.24M -3.55B -54.92M -149M -1.89B -142M -139M -5.98B EV / Sales 2024
1.62x
EV / Sales 2025 23.8x
Free-Float
78.37%
Yield 2024 *
-
Yield 2025 -
1 day-1.58%
1 week-70.86%
Current month-70.86%
1 month-81.46%
3 months-90.46%
6 months-92.40%
Current year-95.46%
1 week 1.3
Extreme 1.3
4.92
1 month 1.3
Extreme 1.3
7.35
Current year 1.3
Extreme 1.3
36
1 year 1.3
Extreme 1.3
36
3 years 1.3
Extreme 1.3
43.4
5 years 1.3
Extreme 1.3
43.4
10 years 1.3
Extreme 1.3
87.9
Manager TitleAgeSince
Chief Executive Officer 54 2013-02-04
Director of Finance/CFO 59 2022-08-31
Chief Tech/Sci/R&D Officer - 2024-09-30
Director TitleAgeSince
Director/Board Member 64 2001-12-31
Director/Board Member 70 2019-04-10
Director/Board Member 62 2022-03-31
Date Insider Type Main position Quantity % Market Cap. Importance
9/4/25 Buy

Chief Executive Officer

6 0.0000%
9/4/25 Free

Chief Executive Officer

1,393 0.0040%
9/3/25 Free 149 0.0004% -
Change 5-day change 1-year change 3-year change Capi.($)
-1.58%-70.86%-94.83%-91.08% 4.84M
-0.79%-4.48%+46.48%+125.69% 1,206B
+1.43%+1.11%+48.05%+83.05% 665B
+1.07%-1.21%+32.92%+104.92% 515B
-0.36%-3.25%+47.17%+64.58% 381B
-0.14%-1.87%+70.06%+41.09% 362B
-0.78%-0.52%+30.57%+57.98% 307B
-0.80%-0.21%+8.54%+35.56% 289B
+0.03%-1.20%+43.79%+69.83% 249B
-0.41%-2.22%+40.43%+107.03% 207B
Average -0.23%-8.47%+27.32%+59.86% 417.97B
Weighted average by Cap. -0.04%-1.96%+42.92%+88.01%

Financials

2024 2025
Net sales 590M 59.72M 53.56M 48.95M 44.68M 84.18M 5.61B 86.84M 235M 3B 224M 219M 9.46B 26M 2.63M 2.36M 2.16M 1.97M 3.71M 247M 3.83M 10.37M 132M 9.88M 9.67M 417M
Net income -203M -20.55M -18.43M -16.84M -15.37M -28.97M -1.93B -29.88M -80.95M -1.03B -77.12M -75.47M -3.25B 639M 64.71M 58.03M 53.04M 48.42M 91.22M 6.08B 94.09M 255M 3.25B 243M 238M 10.25B
Net Debt 353M 35.7M 32.02M 29.26M 26.71M 50.33M 3.36B 51.91M 141M 1.79B 134M 131M 5.65B -421M -42.6M -38.21M -34.92M -31.88M -60.06M -4B -61.95M -168M -2.14B -160M -156M -6.75B
Projected Income Statement - Annual - Orexo AB
Logo Orexo AB
Orexo AB is a Sweden-based company active within the pharmaceutical industry. It focuses primarily on the development of new, patented drugs by combining documented substances with technologies, and the new treatments for respiratory and inflammatory diseases. The Company has four commercialized products, several projects developed in partnership, as well as three development programs. The Company's registered products are: Abstral for the treatment of break through cancer pain, sold by ProStrakan Group plc in Europe, the United States and Canada; the sleeping pill Edluar, sold by Meda in the United States and Canada; as well as two products for the diagnosis of Helicobacter pylori which are being marketed by the subsidiary, Kibion AB. The Company operates through subsidiaries: Pharmacall AB, Noster System AB, Orexo UK, and Pharmakodex Ltd, among others. In December 2013, Kyowa Hakko Kirin Co., Ltd (KHK), with the licensed right to Abstral, commenced the launch of it in Japan.
Employees
55
Date Price Change Volume
26-11-06 SEK 1.368 -1.58% 530,528
26-11-05 SEK 1.390 -4.01% 454,555
26-11-04 SEK 1.448 -3.34% 801,095
26-11-03 SEK 1.498 -64.38% 4,013,077
26-11-02 SEK 4.205 -10.44% 230,073
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Orexo AB

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Orexo AB